Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

Stopped early · Phase 2

Conditions studied: Metastatic Renal Cell Carcinoma

In brief

The purpose of this study is to find out what effects (good and bad) a stem cell transplant from an unrelated donor will have for patients with kidney cancer that has spread to other parts of the body (metastasized).

Key facts

Study ID

NCT00318110

Run by

Center for International Blood and Marrow Transplant Research

People needed

4

Starts

2006-04-01

Expected to finish

2009-03-01

Last updated by the study team

2016-07-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of metastatic (stage IV) renal cell carcinoma (RCC) predominately clear cell type
• Prior nephrectomy
• Available HLA-matched (8/8, 7/8) unrelated donor
• At least one prior immunotherapy; or immunotherapy + chemotherapy; or targeted therapy, for metastatic RCC.
• Adequate organ function

You may not qualify if…

• Prior allogeneic stem cell transplantation
• RCC with histology other than clear cell type
• History or presence of brain metastasis

Where it is running

• University of California - Los Angeles — Los Angeles, California, United States
• Shands - University of Florida — Gainesville, Florida, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.